This trial is active, not recruiting.

Condition chronic kidney disease
Sponsor Seoul National University Hospital
Start date March 2011
End date December 2020
Trial size 2450 participants
Trial identifier NCT01630486, KNOW-CKD


The goals of the KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease) study are 1) to establish a CKD cohort representing Korean CKD population for up to 10-year follow-up, and 2) to investigate the renal progression, mortality, complications, risk factors, role of biochemical parameters and the genetic influence.

KNOW-CKD Research Group comprises nephrologists, pediatric nephrologists, epidemiologists and statisticians from eleven centers in Korea. KNOW-CKD will enroll 2,850 individuals with CKD stage from 1 to 5 between 2011 and 2015 and follow them up to 10 years. Dialyzed patients or those with allograft kidney are excluded. At enrollment and at pre-specified intervals, laboratory tests will be conducted on the kidney function, biochemical profiles, anemia, cardiovascular complication (echocardiography, coronary CT, arterial stiffness), and mineral bone disorder. A biobank is also established for the DNA, serum and urine at regular interval. Information on the medical history, health questionnaires, QoL will also be collected. Web-based case-report forms (CRF) is developed for the systemic management of the patient data.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
adult CKD patients, whose underlying etiology is hypertensive nephropathy
adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
adult CKD patients, whose underlying etiology is diabetic nephropathy

Primary Outcomes

overall mortality
time frame: 10 years

Secondary Outcomes

cardiovascular event
time frame: 10 years
renal replacement therapy
time frame: 10 years
doubling of serum creatinine
time frame: 10 years

Eligibility Criteria

Male or female participants from 20 years up to 75 years old.

Inclusion Criteria: - Age: >20 and <75 yr, - CKD stage 1 through 5 - predialysis Exclusion Criteria: - Unable or unwilling to give consent - Previously received chronic dialysis - Previous any organ transplant - Heart failure - Known liver cirrhosis - past or current cancer - Pregnant women - Single kidney due to trauma or donation

Additional Information

Official title KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Seoul National University Hospital.